Friedman Brain Institute, Department of Neuroscience, Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY 10029
eNeuro. 2022 Aug 3;9(4). doi: 10.1523/ENEURO.0017-22.2022. Print 2022 Jul-Aug.
Replicability, the degree to which a previous scientific finding can be repeated in a distinct set of data, has been considered an integral component of institutionalized scientific practice since its inception several hundred years ago. In the past decade, large-scale replication studies have demonstrated that replicability is far from favorable, across multiple scientific fields. Here, I evaluate this literature and describe contributing factors including the prevalence of questionable research practices (QRPs), misunderstanding of -values, and low statistical power. I subsequently discuss how these issues manifest specifically in preclinical neuroscience research. I conclude that these problems are multifaceted and difficult to solve, relying on the actions of early and late career researchers, funding sources, academic publishers, and others. I assert that any viable solution to the problem of substandard replicability must include changing academic incentives, with adoption of registered reports being the most immediately impactful and pragmatic strategy. For animal research in particular, comprehensive reporting guidelines that document potential sources of sensitivity for experimental outcomes is an essential addition.
可重复性,即先前的科学发现能够在不同数据集上重复的程度,自几百年前其诞生以来,一直被认为是制度化科学实践的一个组成部分。在过去的十年中,大规模的复制研究表明,在多个科学领域,可重复性远非如此。在这里,我评估了这方面的文献,并描述了一些促成因素,包括可疑研究行为(QRPs)的普遍存在、对 p 值的误解以及低统计功效。随后,我讨论了这些问题在临床前神经科学研究中是如何具体表现的。我得出的结论是,这些问题是多方面的,难以解决,需要早期和晚期职业研究人员、资金来源、学术出版商等的共同努力。我断言,要解决可重复性差的问题,任何可行的方案都必须改变学术激励机制,其中采用注册报告是最直接、最具实际意义的策略。对于动物研究来说,详细记录实验结果敏感性潜在来源的全面报告指南是一个必不可少的补充。